KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Non-Current Deferred Tax Liability (2018 - 2025)

Bristol Myers Squibb (BMY) has disclosed Non-Current Deferred Tax Liability for 13 consecutive years, with $225.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Deferred Tax Liability fell 47.67% to $225.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $225.0 million, a 47.67% decrease, with the full-year FY2024 number at $369.0 million, up 9.17% from a year prior.
  • Non-Current Deferred Tax Liability was $225.0 million for Q3 2025 at Bristol Myers Squibb, down from $247.0 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $5.2 billion in Q1 2021 to a low of $225.0 million in Q3 2025.
  • A 5-year average of $1.9 billion and a median of $751.0 million in 2023 define the central range for Non-Current Deferred Tax Liability.
  • Peak YoY movement for Non-Current Deferred Tax Liability: crashed 86.15% in 2023, then rose 9.17% in 2024.
  • Bristol Myers Squibb's Non-Current Deferred Tax Liability stood at $4.5 billion in 2021, then tumbled by 51.88% to $2.2 billion in 2022, then plummeted by 84.4% to $338.0 million in 2023, then rose by 9.17% to $369.0 million in 2024, then crashed by 39.02% to $225.0 million in 2025.
  • Per Business Quant, the three most recent readings for BMY's Non-Current Deferred Tax Liability are $225.0 million (Q3 2025), $247.0 million (Q2 2025), and $276.0 million (Q1 2025).